Eva Harris PhD

Professor, Division of Infectious Diseases and Vaccinology
Director, Center for Global Public Health
Infectious Diseases and Immunity PhD Program Head
  • PH265: Molecular Parasitology (Fall)
  • PH260F: Infectious Disease Research in Developing Countries (Spring)
  • PH292/3: Doctoral Research Seminar (Spring)
  • PH162A: Public Health Microbiology (Fall)
Research Interests: 
  • Molecular virology, pathogenesis, immunology, epidemiology, clinical aspects, and control of dengue, Zika, and chikungunya
  • Epidemiology of influenza in tropical countries
  • Scientific capacity building in developing countries
Research Description: 

Professor Harris has developed a multidisciplinary approach to study the molecular virology, pathogenesis, immunology, epidemiology, clinical aspects, and control of dengue, Zika, and chikungunya—the most prevalent mosquito-borne diseases in humans. Her work investigates viral and host factors that modulate disease severity and immune correlates of protection and pathogenesis, using in vitro approaches, animal models, and research involving human populations. One major focus is on studies of arboviral diesase in humans, including antibody and B cell responses and correlates of protection; systems immunology profiling of the innate response; and viral evolution, fitness, and intrahost diversity. Another focus is viral pathogenesis, specifically the role of NS1 protein in vascular leak and ZIKV infection of the human placenta. Her international work focuses on laboratory-based and epidemiological studies of dengue, Zika, chikungunya, and influenza in endemic Latin American countries, particularly in Nicaragua, where she has been working closely with the Ministry of Health for over 30 years. Long-term collaborations include clinical, biological, and immunological studies of severe disease through a 20-year pediatric hospital-based study; a 15-year ongoing pediatric cohort study of dengue, Zika, chikungunya, and influenza transmission in Managua; and a cluster randomized controlled trial of evidence-based community-derived interventions to prevent and control arboviral diseases.

Selected Publications: 

Zambrana, J.V., Bustos, F., Burger-Calderon, R., Collado, D., Jairo, Sanchez, N., Ojeda, S., Plazaola, M., Lopez, B., Arguello, S., Elizondo, D., Aviles, W., Kuan, G., Balmaseda, A., Gordon, A., Harris, E. (2018) Seroprevalence, risk factor, and spatial analysis of Zika virus infection after the 2016 epidemic in Managua, Nicaragua. Proc. Natl. Acad. Sci. USA. [In press].

Gordon, A., Gresh, L., Ojeda, S., Chowell-Puente, G., Gonzalez, K., Sanchez, N., Saborio, S., Mercado, J.C., Kuan, G., Balmaseda, A., and Harris, E. (2018) Differences in transmission and disease severity between two successive waves of chikungunya. Clin. Infect. Dis. 2018 Apr 25. doi: 10.1093/cid/ciy356. [Epub ahead of print].

Katzelnick., L. Gresh, L, Halloran, M.E., Mercado, J.C., Kuan, G., Gordon, A., Balmaseda, A., and Harris, E. (2017) Antibody-dependent enhancement of severe dengue disease in humans. Science. 358(6365):929-932.
Montoya, M., Collins, M., Dejnirattisai, W., Katzelnick, L.C., Puerta-Guardo, H., Jadi, R., Schildhauer, S., Supasa, P., Vasanawathana, S., Malasit, P., Mongkolsapaya, J., de Silva, A.D., Tissera, H., Balmaseda, A., Screaton, G., de Silva, A.M., Harris, E. (2018) Longitudinal analysis of antibody cross-neutralization following Zika and dengue virus infection in Asia and the Americas. J. Infect. Dis. 218(4):536-545

Michlmayr, D., Andrade, P., Gonzalez, K., Balmaseda, A., and Harris E. (2017) CD14+ CD16+ monocytes are the main targets of Zika virus infection in peripheral blood mononuclear cells in a paediatric study in Nicaragua. Nat Microbiol. 2(11):1462-1470.

Glasner, D.R., Ratnasiri, K., Puerta-Guardo, H., Beatty, P.R., and Harris, E. (2017) Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx integrity. PLoS Pathog. 13(11):e1006673.

Andrade, D.V., Katzelnick, L.C., Widman, D.G., Balmaseda, A., de Silva A.M., Baric, R.S., and Harris, E. (2017) Analysis of individuals from a dengue-endemic region helps define the footprint and repertoire of antibodies targeting dengue virus 3 type-specific epitopes. mBio. 8(5):e01205-17

Parameswaran, P., Wang, C., Trivedi, S.B., Eswarappa, M., Montoya, M., Balmaseda, A., and Harris, E. (2017) Intrahost selection pressures drive rapid dengue virus microevolution in acute human infections. Cell Host Microbe. 22(3):400-410.e5.

Tabata, T., Petitt, M., Puerta-Guardo, H., Michlmayr, D., Wang, C., Fang-Hoover, J., Harris, E.* and Pereira, L.* (2016) Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe. In press (Epub July 18, 2016) S1931-3128(16)30300-6. doi: 10.1016/j.chom.2016.07.002. *Co-corresponding authors. 

Puerta-Guardo, H., Glasner, D.R., and Harris, E. (2016) Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability. PLoS Pathog. 12(7):e1005738.

Beatty, P.R., Puerta Guardo, H., Killingbeck, S., Glasner, D., Hopkins, K., and Harris, E. (2015) Dengue virus non-structural protein 1 (NS1) triggers vascular leak that can be inhibited by anti-NS1 antibodies. Sci Transl Med. 7:304ra141.

Andersson, N., Nava-Aguilera, E., Arostegui, J., Morales-Perez, A., Suazo-Laguna, H., Legorreta-Soberanis, J., Hernandez-Alvarez, C., Fernandez-Salas, I., Balmaseda, A., Cortés-Guzmán, A.J., Coloma, J., Ledogar, R.J., and Harris, E. (2015) Camino Verde (Green Way) to Dengue Prevention: a pragmatic cluster-randomised controlled trial of evidence-based community mobilisation in Nicaragua and Mexico. BMJ. 351:h3267.

Other interests: 
  • President, Sustainable Sciences Institute
  • Director, Center for Global Public Health
  • Infectious Diseases and Immunity Graduate Group (Chair)
  • Microbial Biology Graduate Group
Profile Updated: October 5, 2018